CN104803946A - PTP1B (protein tyrosine phosphatase 1B) inhibitors with thiazolecarbonitrile and cyclopentadiene structures and application of inhibitors - Google Patents
PTP1B (protein tyrosine phosphatase 1B) inhibitors with thiazolecarbonitrile and cyclopentadiene structures and application of inhibitors Download PDFInfo
- Publication number
- CN104803946A CN104803946A CN201510094856.4A CN201510094856A CN104803946A CN 104803946 A CN104803946 A CN 104803946A CN 201510094856 A CN201510094856 A CN 201510094856A CN 104803946 A CN104803946 A CN 104803946A
- Authority
- CN
- China
- Prior art keywords
- compound
- inhibitors
- ptp1b
- application
- thiazolecarbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of medicine related to type-2 diabetes mellitus, in particular to PTP1B (protein tyrosine phosphatase 1B) inhibitors with thiazolecarbonitrile and cyclopentadiene structures, preparation methods of the PTP1B inhibitors and an application of the PTP1B inhibitors in preparation of the medicine for treating type-2 diabetes mellitus.
Description
Technical field
The present invention relates to the pharmaceutical field of diabetes B treatment.More particularly, the present invention relates to PTP1B inhibitor, its preparation method to the medicative class nitrile group-containing thiazole of diabetes B tool and cyclopentadiene structure, and the purposes in pharmacy.
Background technology
Diabetes B is a kind of common metabolic disturbance diseases, it is characterized in that periphery produces resistant function to film island element, shows as Regular Insulin to be combined signal transduction afterwards with insulin receptor and to lack at molecular level.The phosphorylation level of proteolytic enzyme propylhomoserin is the important regulate factors of intracellular signal transduction, it is by proteolytic enzyme histidine kinase (protein tyrosine kinase, PTK) and proteolytic enzyme propylhomoserin Phosphoric acid esterase (protein tyrosine phosphatase, PTP) jointly regulate and control.Research in recent years finds, proteolytic enzyme propylhomoserin phosphatase 1 B can dephosphorylation proteolytic enzyme propylhomoserin, plays important negative regulation effect in Insulin signaling pathway.Knock out PTPIB gene, or use antisense core former times acid (ASO) to suppress the expression of PTP1B albumen and mRNA in body, not only can significantly improve the susceptibility of test mice to Regular Insulin, and obviously can reduce the ill probability of obesity.These researchs show, PTP1B likely becomes the novel targets for the treatment of type ii diabetes.
The invention discloses the nitrile group-containing thiazole of a class formation novelty and the PTP1B inhibitor of cyclopentadiene structure, these compounds can be used for the medicine preparing treatment diabetes B.
Summary of the invention
An object of the present invention is to provide a kind of PTP1B inhibitor with the excellent activity of general formula I.
Another object of the present invention is to provide the method that preparation has the compound of general formula I.
The compound that another object of the present invention is to provide containing general formula I is treating the application in diabetes B as effective constituent.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula (I) has following structural formula:
The compound of preferred formula (I) has following structure,
General formula of the present invention (I) compound is synthesized by following route:
Compound V can be prepared according to literature method (rising sun is paid in war, etc., containing the design of the inhibitors of dipeptidyl IV of thiazole ring, synthesis and hypoglycemic activity research, organic chemistry, 2009,29 (8), 1236-1242).
Compound II per is first obtained by reacting its corresponding sylvite with KOH, and the latter reacts with compound III again, obtains compound IV; Compound IV is first obtained by reacting its corresponding sylvite with KOH, and the latter reacts with V again, obtains Compound I; Wherein, the definition of R as previously mentioned.
Compound of Formula I of the present invention has the restraining effect of PTP1B, can be used as effective constituent for the preparation of diabetes B medicine.The activity of compound of Formula I of the present invention is verified by receptor binding assays.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
embodiment
1
compound
i-1
synthesis
A. the synthesis of compound IV
Compound II per (1.32g, 20mmol) be dissolved in 10mL DMSO, stir, add solid KOH (2.81g, 50mmol), continue stirring under room temperature 1 hour, then add compound III (5.86g, 24mmol), gained mixture at room temperature stirs and spends the night, and TLC checks and finds that reaction completes.Reaction mixture pours in 150mL frozen water, stirs, and uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV, white solid.ESI-MS,m/z＝230([M+H]
+)。
B. the synthesis of Compound I-1
Compound IV (2.29g, 10mmol) be dissolved in 20mL DMSO, stir, add solid KOH (2.81g, 50mmol), continue stirring under room temperature 1 hour, then add compound V-1 (3.32g, 12mmol), gained mixture at room temperature stirs and spends the night, and TLC checks and finds that reaction completes.Reaction mixture pours in 150mL frozen water, stirs, and uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I-1, white solid.ESI-MS,m/z＝471([M+H]
+)。
embodiment
2-3
With reference to the method for embodiment 1, synthesize compound listed in Table.
embodiment
4
compound
d-1
synthesis
Compound D-1 is all the compound (not yet open by the applying date) that the present inventor designs in research process.
A. the synthesis of compound IV-4
Compound II per (1.32g, 20mmol) be dissolved in 10mL DMSO, stir, add solid KOH (2.81g, 50mmol), continue stirring under room temperature 1 hour, then add compound III-4 (5.14g, 24mmol), gained mixture at room temperature stirs and spends the night, and TLC checks and finds that reaction completes.Reaction mixture pours in 150mL frozen water, stirs, and uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-4, white solid.ESI-MS,m/z＝200([M+H]
+)。
B. the synthesis of Compound D-1
Compound IV-4 (1.99g, 10mmol) be dissolved in 20mL DMSO, stir, add solid KOH (2.81g, 50mmol), continue stirring under room temperature 1 hour, then add compound V-4 (2.29g, 12mmol), gained mixture at room temperature stirs and spends the night, and TLC checks and finds that reaction completes.Reaction mixture pours in 150mL frozen water, stirs, and uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound D-1, white solid.ESI-MS,m/z＝354([M+H]
+)。
embodiment
5
compound ira vitro pair
pTP1B
inhibition test
Be that the compound solution 95%DMSO of 50mM carries out 1/2 gradient dilution by original concentration, dilute 11 concentration gradients altogether.Enzyme reaction system alive amounts to 102 μ L, and wherein compound adds volume is 2 μ L.First, in 96 orifice plates, add 50 μ L PTP1B albumen successively, the testing compound of 2 μ L different concns, concussion 1min, hatches 30min for 30 DEG C, then adds 50 μ L pNPP (para-nitro-pheneye phosphate), concussion 10s.Under mensuration 405nm wavelength, absorbancy is with the change in reaction times, within 6 seconds, survey once, survey 60 points, replicate(determination) three times, and draw out reaction process curve, thus under calculating different concns each compound to the inhibit activities of enzyme, software GraphPad Prism 5 software is utilized to carry out non linear fit analysis, with remaining activity value for ordinate zou, compound concentration logarithmic value is X-coordinate curve plotting, calculates the IC of this compound
50value.Test result sees the following form.
| Compound | IC 50(nM) |
| Reference compound D-1 (embodiment 4) | 18.4 |
| Compound I-1 | 7.6 |
| Compound I-2 | 8.2 |
| Compound I-3 | 10.7 |
As can be seen from upper table result, compound of the present invention has very strong restraining effect to PTP1B, can as the medicine of preparation treatment diabetes B.
Claims (4)
1. there is the compound of general formula I,
2. the compound of Formula I that defines of claim 1, is selected from:
3. synthesize arbitrary the defined method belonging to the compound of general formula I of claim 1-2:
Compound II per is first obtained by reacting its corresponding sylvite with KOH, and the latter reacts with compound III again, obtains compound IV; Compound IV is first obtained by reacting its corresponding sylvite with KOH, and the latter reacts with V again, obtains Compound I.
4. the compound of Formula I that one of claim 1-2 defines is preparing the application in treatment diabetes B medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510094856.4A CN104803946A (en) | 2015-03-03 | 2015-03-03 | PTP1B (protein tyrosine phosphatase 1B) inhibitors with thiazolecarbonitrile and cyclopentadiene structures and application of inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510094856.4A CN104803946A (en) | 2015-03-03 | 2015-03-03 | PTP1B (protein tyrosine phosphatase 1B) inhibitors with thiazolecarbonitrile and cyclopentadiene structures and application of inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104803946A true CN104803946A (en) | 2015-07-29 |
Family
ID=53689185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510094856.4A Pending CN104803946A (en) | 2015-03-03 | 2015-03-03 | PTP1B (protein tyrosine phosphatase 1B) inhibitors with thiazolecarbonitrile and cyclopentadiene structures and application of inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104803946A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080057068A1 (en) * | 2002-02-28 | 2008-03-06 | Dalton James T | SARMS and method of use thereof |
| US20130137728A1 (en) * | 2010-03-24 | 2013-05-30 | MUSC Foundation for Research and Development | Compositions and Methods for the Treatment of Degenerative Diseases |
| WO2013189841A1 (en) * | 2012-06-19 | 2013-12-27 | F. Hoffmann-La Roche Ag | New bicyclic thiophenylamide compounds |
| US20140088148A1 (en) * | 2011-04-04 | 2014-03-27 | Georgetown University | Small molecule inhibitors of xbp1 splicing |
-
2015
- 2015-03-03 CN CN201510094856.4A patent/CN104803946A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080057068A1 (en) * | 2002-02-28 | 2008-03-06 | Dalton James T | SARMS and method of use thereof |
| US20130137728A1 (en) * | 2010-03-24 | 2013-05-30 | MUSC Foundation for Research and Development | Compositions and Methods for the Treatment of Degenerative Diseases |
| US20140088148A1 (en) * | 2011-04-04 | 2014-03-27 | Georgetown University | Small molecule inhibitors of xbp1 splicing |
| WO2013189841A1 (en) * | 2012-06-19 | 2013-12-27 | F. Hoffmann-La Roche Ag | New bicyclic thiophenylamide compounds |
Non-Patent Citations (2)
| Title |
|---|
| 战付旭 等: "含噻唑环的二肽基肽酶 IV抑制剂的设计、合成和降血糖活性研究", 《有机化学》 * |
| 战付旭 等: "含噻唑环的新型二肽基肽酶Ⅳ抑制剂的设计合成及其降血糖作用", 《中国药物化学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gitto et al. | Identification of 3, 4-Dihydroisoquinoline-2 (1 H)-sulfonamides as Potent Carbonic Anhydrase Inhibitors: Synthesis, Biological Evaluation, and Enzyme− Ligand X-ray Studies | |
| Krumpel et al. | The small chemical enzyme inhibitor 5-phenylnicotinic acid/CD13 inhibits cell migration and invasion of tartrate-resistant acid phosphatase/ACP5-overexpressing MDA-MB-231 breast cancer cells | |
| CN104803946A (en) | PTP1B (protein tyrosine phosphatase 1B) inhibitors with thiazolecarbonitrile and cyclopentadiene structures and application of inhibitors | |
| CN104803939A (en) | PTP1B (protein tyrosine phosphatase 1B) inhibitors with nitrothiazole and cyclopentadiene structures and application of inhibitors | |
| CN104803940A (en) | PTP (protein tyrosine phosphatase)1B compounds containing thiazole and cyclopentadiene structures and application of PTP1B compounds | |
| CN104744397A (en) | PTP1B inhibitor containing cyclopentadiene and cyanoaniline structures and use of PTP1B inhibitor | |
| CN104803938A (en) | PTP1B (protein tyrosine phosphatase 1B) inhibitors with phenylthiazole and cyclopentadiene structures and application of inhibitors | |
| CN105037187B (en) | Metal Zn complex of serine N derivatives and its preparation method and application | |
| CN104829552A (en) | PTP1B inhibitor containing cyclopentadiene and aniline structures and application thereof | |
| CN104803937A (en) | Derivatives containing cyclopentadiene and aniline structures and applications of derivatives | |
| CN104803944A (en) | Compounds containing cyclopentadiene and aniline structures and applications of compounds | |
| CN104803942A (en) | PTP (protein tyrosine phosphatase)1B inhibitors containing cyclopentadiene and alkoxyaniline structures and application of PTP1B inhibitors | |
| CN104744396A (en) | PTP1B inhibitor containing cyclopentadiene structure, preparation method of PTP1B inhibitor and use of PTP1B inhibitor | |
| CN104803943A (en) | PTP (protein tyrosine phosphatase)1B inhibitors containing cyclopentadiene and thioaniline structures and application of PTP1B inhibitors | |
| CN104803945A (en) | PTP (protein tyrosine phosphatase)1B inhibitors containing phenylthiazole and cyclopentadiene structures and application of PTP1B inhibitors | |
| CN104744398A (en) | PTP1B inhibitor containing halogenobenzothiazole and cyclopentadiene structures and use of PTP1B inhibitor | |
| CN104803941A (en) | PTP1B (protein tyrosine phosphatase 1B) inhibitors with cyclopentadiene structures, preparation methods and application of inhibitors | |
| CN110256465A (en) | A kind of 2,4- di-amino-pyrimidine and its application containing dihydropyran and thiazole | |
| CN104803931A (en) | PTP (protein tyrosine phosphatase)1B inhibitors containing tetrazole structure as well as preparation methods and application of PTP1B inhibitors | |
| CN104803933A (en) | PTP1B inhibitors containing tetrazole structures as well as preparation methods and applications of inhibitors | |
| CN104744387A (en) | PTP1B inhibitor containing tetrazole and halobenzene structures, preparation method of PTP1B inhibitor and use of PTP1B inhibitor | |
| CN104803932A (en) | PTP (protein tyrosine phosphatase)1B inhibitors containing tetrazole structures and application of PTP1B inhibitors | |
| Aguilar-Alonso et al. | MAPKs’ status at early stages of renal carcinogenesis and tumors induced by ferric nitrilotriacetate | |
| CN104803977A (en) | PTP1B derivatives containing tetrazole structures as well as preparation methods and applications of derivatives | |
| CN104744386A (en) | PTP1B inhibitor containing tetrazole structure and use of PTP1B inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150729 |
|
| WD01 | Invention patent application deemed withdrawn after publication |